Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342433 · ClinicalTrials.gov registry record
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 553
- Enrollment target
NCT00342433: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342433 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 553 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342433 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 553 participants
- Enrollment target
Study Summary
Although compelling evidence from laboratory studies suggests that androgens play a major role in prostate carcinogenesis, epidemiologic studies in humans (almost exclusively serologic studies) have been unable to confirm the hormonal hypothesis. The major limitation in these serologic studies may stem from difficulty in measuring androgenicity directly at the target site - the prostate. If circulating hormones do not reflect intraprostatic hormone levels or androgenicity, it is not clear how we should interpret results from serum/plasma measurements, and it is unlikely that future serologic studies can clarify the role of hormones in prostate cancer etiology. This study is a comprehensive methodologic study designed to collect venous blood and prostatic tissue from 650 patients (100 Chinese, 500 American, and 50 Italian) undergoing prostatic surgery (radical prostatectomy, cystoprostatectomy, or transurethral resection of the prostate) in order to correlate prostate tissue with serum hormone levels, and with polymorphisms of hormone-related genes (including the androgen receptor and SRD5A2, the gene encoding 5-alpha-reductase Type II), and to examine characteristics (such as age, smoking, body size) that might affect serum-tissue correlation. We plan to study the following hormones: testosterone, dihydrotestosterone, androstenedione, androstandediol glucuronide, estradiol, estrone, and estrone sulfate. Levels of androgen receptor and its associated protein in prostatic tissue will also be measured to provide a better estimate of total intraprostatic androgenicity. We also plan to collect saliva from 100 of these cases in the Washington, D.C. area and 100 of these cases in China, to assess whether this non-invasive tissue collection method is valid for hormone measurements. Finally, urine collection from 100 of these Chinese men is planned for study of androgen metabolites. Additionally, we plan to include 200 Chinese subjects for blood collection without tumor ti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 1999-05-05 |
| Est. Completion | 2020-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342433
The ClinicalTrials.gov registry entry for NCT00342433 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 553 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00342433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00342433 about?
NCT00342433 is a clinical study titled "Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study". Although compelling evidence from laboratory studies suggests that androgens play a major role in prostate carcinogenesis, epidemiologic studies in humans (almost exclusively serologic studies) have been unable to confirm the hormonal hypothesis. The major limitation in these serologic studies may s...
What is the current status of trial NCT00342433?
This trial is currently completed. The enrollment target is 553 participants. The study started on 1999-05-05. Estimated completion is 2020-05-15.
Who is sponsoring clinical trial NCT00342433?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.